ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3037% below fair value
$13.24+0.05 (+0.38%)
Close on Nov 12, 2026Market cap $2.97BP/E 17.2Yield –
ADMA Biologics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
ADMA Biologics's enterprise value was $3.03B on Nov 11, 2026, against $4.58B a year earlier. Over the last 5 years it ranged from $160.61M to $5.60B, with a median of $2.00B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.03B | -30.4% |
| 2025 | Dec 31, 2025 | $4.36B | +9.9% |
| 2024 | Dec 31, 2024 | $3.97B | +318.8% |
| 2023 | Dec 29, 2023 | $947.17M | +30.0% |
| 2022 | Dec 30, 2022 | $728.59M | +353.6% |
| 2021 | Dec 31, 2021 | $160.61M | -18.5% |
| 2020 | Dec 31, 2020 | $197.19M | -23.3% |
| 2019 | Dec 31, 2019 | $257.11M | +183.9% |
| 2018 | Dec 31, 2018 | $90.57M | +61.3% |
| 2017 | Dec 29, 2017 | $56.15M | -7.7% |
| 2016 | Dec 30, 2016 | $60.84M | -23.6% |
| 2015 | Dec 31, 2015 | $79.63M | -14.7% |
| 2014 | Dec 31, 2014 | $93.38M | +106.3% |
| 2013 | Dec 31, 2013 | $45.25M | – |
See a number that looks wrong?